Biomedical Diagnostics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

28.10.19	PredictImmune Announces a Strategic Agreement With Theradiag for French Speaking Europe to Commercialise PredictSURE IBD™, the World’s First Validated Prognostic Test for Inflammatory Bowel Disease (Businesswire)
28.02.18	THERADIAG: Keen Interest from the Scientific Community for Biotherapy Monitoring During the ECCO Congress (Businesswire)
20.02.18	Theradiag: Full-Year 2017 Revenue and End of 2017 Cash Position (Businesswire)
19.01.18	Miraca Life Sciences, Theradiag’s Partner in the USA, Becomes Inform Diagnostics (Businesswire)
21.12.17	THERADIAG Signs a Partnership Agreement for Monitoring of Remicade® (Businesswire)
19.12.17	THERADIAG Provides an Update on Prestizia and Its Partnership with HOB Biotech (Businesswire)
14.11.17	Theradiag and Biogen Sign a Partnership Agreement (Businesswire)
26.10.17	Theradiag: Revenues at the End of September 30, 2017 (Businesswire)
16.10.17	Eighth Test in Theradiag’s Monitoring Range Launched in the USA (Businesswire)
25.07.17	Theradiag: Further Strong Sales Growth in the First Half of 2017: +9% (Businesswire)
28.11.16	Theradiag Wins the Ile de France (Paris) Chamber of Commerce and Industry Award for Its Export Activities (Businesswire)
13.10.16	Theradiag: Very Strong Revenue Growth at End-September 2016: +31% (Businesswire)
10.10.16	Theradiag: Substantial Potential Reduction in Treatment Costs Thanks to Biotherapy Monitoring (Businesswire)
14.09.16	Theradiag: First-Half 2016 Revenues and Results (Businesswire)
14.09.16	Theradiag Carries out a Capital Increase Fully Subscribed by Its Chinese Partner HOB Biotech (Businesswire)
05.09.16	LISA TRACKER® Chosen by Janssen Biotech for Its Program to Monitor Patients Treated with Remicade® in the USA (Businesswire)
11.07.16	Vincent Fert Appointed to Theradiag’s Board of Directors (Businesswire)
05.07.16	Theradiag: Very Strong Revenue Growth in the First Half of 2016: +36% (Businesswire)
16.06.16	Theradiag: LISA TRACKER® Launched in the US Market (Businesswire)
25.04.16	Theradiag: First-Quarter 2016 Revenues up 50% (Businesswire)
06.04.16	Theradiag: Launch of a New Fully Automated Diagnostics System (Businesswire)
22.03.16	Theradiag: Biotherapy Monitoring, a Major Area of Interest at the European Crohn’s and Colitis Organisation (ECCO) Congress (Businesswire)
15.03.16	Theradiag Presents at JFHOD the Results of a microRNA Signature Predicting a Patient’s Therapeutic Response in Locally Advanced Rectal Cancer (Businesswire)
10.03.16	Theradiag: Full-Year 2015 Results (Businesswire)
08.02.16	Theradiag: 2015 Revenues: Very Strong Sales Growth of LISA TRACKER® Kits (Businesswire)
14.01.16	Theradiag: 2016 Financial calendar (Businesswire)
14.12.15	Theradiag Expands Its Biotherapy Monitoring Range, with a New CE Marking Obtained for its Entyvio® Test (Businesswire)
08.12.15	Theradiag: Results of the ROC Trial Demonstrate the Benefits of Monitoring Biotherapies (Businesswire)
20.11.15	THERADIAG renews the Standby Equity Facility (SEF®) with Société Générale (Businesswire)
18.11.15	Theradiag and HOB Biotech Sign a Strategic Partnership in Asia and in Europe (Businesswire)
18.11.15	Theradiag Announces Strategic Agreement with Miraca Life Sciences in the USA (Businesswire)
26.10.15	Theradiag Receives Frost & Sullivan 2015 European Theranostics Product Leadership Award During Excellence in Best Practices Awards 2015 Ceremony (Businesswire)
30.09.15	Theradiag: Financial and Operational Results for the First Half of 2015 (Businesswire)
22.07.15	Theradiag Signs Collaboration Agreements with UNICANCER and Bordeaux University Hospital to Advance Micro RNA Project in Rectal Cancer (Businesswire)
17.06.15	Theradiag: New study shows predictive role of theranostics in Inflammatory Bowel Disease (Businesswire)
26.05.15	Theradiag Receives Frost & Sullivan 2015 European Theranostics Product Leadership Award (Businesswire)
20.05.15	Theradiag and Hospira Sign a Partnership Agreement (Businesswire)
11.05.15	Theradiag Launches LISA TRACKER in Canada (Businesswire)
29.04.15	Monitoring of infliximab and C-Reactive Protein can Predict Loss of Response in Inflammatory Bowel Disease (Businesswire)
25.03.15	THERADIAG Receives CE Marking for Its 10th Biotherapy Monitoring Test (Businesswire)
23.03.15	Theradiag Strong Presence at 2015 JFHOD Meeting (Businesswire)
18.03.15	Theradiag Reinforces Its R&D and Production Capacities in New State-of-the-Art Facility (Businesswire)
11.03.15	THERADIAG Strengthens Its Positioning in the Oncology Theranostics Market with Its Herceptin® Monitoring Test Receiving CE Marking (Businesswire)
04.03.15	Theradiag: Full Year Results 2014 (Businesswire)
03.02.15	Theradiag and UCB Enter into a Master Services Agreement (Businesswire)
20.01.15	Theradiag: Revenues 2014: Strong Increase in Theranostics Sales and Return to Growth of Total Revenues (Businesswire)
15.01.15	THERADIAG Renews the Standby Equity Facility (SEF®) with Société Générale (Businesswire)
06.01.15	Theradiag: 2015 Financial Calendar (Businesswire)
29.10.14	Theradiag : Growing Interest in Biotherapy Monitoring in IBD (Businesswire)
14.10.14	THERADIAG: Creation of an Experts Committee for the miCRA Project (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	65.34	3.13 %	K V
Part Grp Hldg	1’099.00	2.42 %	K V
ABB	45.36	2.35 %	K V
Sika	208.70	2.20 %	K V
UBS Group	25.92	1.93 %	K V
Zurich Insur Gr	589.60	-0.61 %	K V
Lonza Grp	574.00	-0.66 %	K V
Novartis	91.20	-0.68 %	K V
Roche Hldg G	261.70	-1.69 %	K V
Swisscom	535.00	-1.92 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Biomedical Diagnostics Aktie VALOR 1599160 / ISIN FR0004197747

Nachrichten zu Biomedical Diagnostics

Aktien Top/Flop

Meistgelesene Nachrichten